Supplements - Synopses of Evidence Review Group reports

In November 2005, NICE introduced its new Single Technology Appraisals process. Since then, the HTA programme has supported the work of the Appraisal committees, by commissioning the Evidence Review Group (ERG) reports (available below as an archive) which critically appraise submissions from manufacturers. Between 2009 and 2011, synopses of ERG reports appeared in Supplements to the HTA journal series. From November 2011, research teams were no longer required to submit the synopses.

Last updated: 8 February 2012 - Next update due: 15 February 2012

Supplements - newest appears first

• Volume 15, Supplement 1.

  Compendium of synopses for Evidence Review Group reports in support of NICE Single Technology Appraisal process. Click on titles below to view (pdf format).
  
  
1. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
2. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years
3. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP)
4. Trastuzumab for the treatment of HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
5. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief
6. Denosumab for the prevention of osteoporotic fractures in postmenopausal women
7. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
8. Trabectedin for the treatment of relapsed ovarian cancer
9. Liraglutide for the treatment of type 2 diabetes
10. Golimumab for the treatment of psoriatic arthritis



• Volume 14, Supplement 2.

  Compendium of synopses for Evidence Review Group reports in support of NICE Single Technology Appraisal process. Click on titles below to view (pdf format).
  
  
1. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
2. Capecitabine for the treatment of advanced gastric cancer
3. Rituximab for the treatment of relapsed/ refractory chronic lymphocytic leukaemia
4. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche
5. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
6. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
7. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
8. Dronedarone for the treatment of atrial fibrillation and atrial flutter
9. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours
10. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer



• Volume 14, Supplement 1.

  Compendium of synopses for Evidence Review Group reports in support of NICE Single Technology Appraisal process. Click on titles below to view (pdf format).
  
  
1. Cetuximab for the first-line treatment of metastatic colorectal cancer
2. Infliximab for the treatment of acute exacerbations of ulcerative colitis
3. Sorafenib for the treatment of advanced hepatocellular carcinoma
4. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
5. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
6. Alitretinoin for the treatment of severe chronic hand eczema
7. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
8. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix
9. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma
10. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia



• Volume 13, Supplement 3.

  Compendium of synopses for Evidence Review Group reports in support of NICE Single Technology Appraisal process. Click on titles below to view (pdf format).
  
  
1. Lapatinib for the treatment of HER2- overexpressing breast cancer
2. Infliximab for the treatment of ulcerative colitis
3. Rimonabant for the treatment of overweight and obese people
4. Telbivudine for the treatment of chronic hepatitis B infection
5. Entecavir for the treatment of chronic hepatitis B infection
6. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal
7. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
8. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
9. Ustekinumab for the treatment of moderate to severe psoriasis



• Volume 13, Supplement 2.

  Compendium of synopses for Evidence Review Group reports in support of NICE Single Technology Appraisal process. Click on titles below to view (pdf format).
  
  
1. Gemcitabine for the treatment of metastatic breast cancer
2. Varenicline in the management of smoking cessation: a single technology appraisal
3. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal
4. Rituximab for the treatment of rheumatoid arthritis
5. Omalizumab for the treatment of severe persistent allergic asthma
6. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
7. Adalimumab for the treatment of psoriasis
8. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal
9. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal
10. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer



• Volume 13, Supplement 1.

  Compendium of synopses for Evidence Review Group reports in support of NICE Single Technology Appraisal process. Click on titles below to view (pdf format).
  
  
1. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2. Docetaxel for the adjuvant treatment of early breast cancer
3. The use of paclitaxel in the management of early stage breast cancer
4. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
5. Bortezomib for the treatment of multiple myeloma patients
6. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
7. Erlotinib for the treatment of relapsed non-small cell lung cancer
8. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
9. Infliximab for the treatment of adults with psoriasis

You can comment on individual synopses and on the Supplement format on the HTA website Correspondence Page.

Online ordering of printed copies is not available for Supplements. Please contact our Despatch Agents directly. View ordering details.

What's related:

• Published research - full listing
• Research in progress
• Evidence Review Group reports

HTA news service:

• News feeds
• Follow NIHR on Twitter

•